You are viewing an incomplete version of our website. Please click to reload the website as full version.

E-cadherin antibody (Cadherin 1, Type 1, E-Cadherin (Epithelial))

Details for Product anti-CDH1 Antibody No. ABIN335399, Supplier: Log in to see
Antigen
  • AA960649
  • arc-1
  • Arc-1
  • Arc1
  • b-cadherin
  • cadherin-1
  • CD324
  • cd324
  • cdh1
  • cdh1-a
  • cdhc-A
  • cdhe
  • CDHE
  • cdhp
  • E-Cad
  • E-cad
  • E-cadherin
  • ecad
  • Ecad
  • ECAD
  • hjmd
  • L-CAM
  • l-cam
  • lcam
  • LCAM
  • pcad
  • si:dz180o5.2
  • Um
  • uvo
  • UVO
  • uvomorulin
  • xb-cad
  • XB-cadherin
  • XBcad
  • xcdh1
  • XTCAD-1
Reactivity
Human
621
161
96
25
21
12
6
5
4
3
3
2
1
1
1
1
1
1
1
1
1
1
Host
Mouse
376
262
26
18
1
1
Clonality (Clone)
Monoclonal ()
Conjugate
This E-cadherin antibody is un-conjugated
38
31
27
17
16
14
14
10
10
9
8
8
8
8
8
8
8
7
7
7
6
5
4
3
3
3
3
3
2
2
1
1
Application
Immunocytochemistry (ICC), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (IHC), Western Blotting (WB)
488
218
190
168
134
126
104
98
64
32
12
9
6
4
2
2
2
2
2
1
1
1
1
1
1
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Immunogen 6F9 is a mouse monoclonal IgG1 antibody obtained by fusion of P3-X63-Ag 8,653 mouse myeloma cells with spleen cells from a BABL/c mouse immunized with affinity purified 80 kD extracellular fragments of E-cadherin derived from tryptic digestion of A-431 human vulva carcinoma cells.
Clone 6F9
Isotype IgG1
Specificity Human.
Purification Purified
Alternative Name E-Cadherin / Cadherin-1 (CDH1 Antibody Abstract)
Background Cadherins constitute a family of transmembrane glycoproteins involved in Ca 2+ -dependent cell-cell interactions. The members of this family are differentially expressed in various tissues. They function in the maintenance of tissue integrity and morphogenesis. Cadherins are divided into type I and type II subgroups. Type I cadherins include epithelial cadherin (E-cadherin, cadherin-1 or uvomorulin), neural cadherin (N-cadherin or cadherin-2), placental cadherin (P-cadherin or cadherin-3) and retinal cadherin (R-cadherin or cadherin-4), whereas kidney cadherin (K-cadherin or cadherin-6) and osteoblast cadherin (OB-cadherin or cadherin-11) are type II cadherins. One of the best characterized cadherins is E-cadherin, a 120 kD transmembrane glycoprotein consisting of an 80 kD extracellular and a 40 kD transmembrane and cytoplasmic part. The extracellular domains of E-cadherin are responsible for calcium binding which allows for homophilic interaction with other E-cadherin molecules on the same cell and neighbouring cells. In addition, E-cadherin can interact heterophilically with integrin alpha E beta 7 . The cytoplasmic domain of E-cadherin is linked to the actin cytoskeleton through the associated cytoplasmic catenin proteins, thus establishing a complex localized to adherens junctions. In carcinomas E-cadherin is frequently downregulated, which is consistent with its function of an invasion suppressor in normal epithelia.
Application Notes 6F9 recognizes both the 120 kD E-cadherin and its 80 kD trypsin-resistant extracellular part. 6F9 is suitable for immunoblotting, immunocytochemistry and immunohistochemistry on frozen when using a PBS buffer containing 0.1 mM CaCl 2 and 0.1 mM MgCl 2 . Optimal antibody dilution should be determined by titration, recommended range is 1:25 - 1:100 for immunohistochemistry with avidin-biotinylated horseradish peroxidase complex (ABC) as detection reagent, and 1:50 - 1:500 for immunoblotting applications.
Restrictions For Research Use only
Storage 4 °C
Product cited in: Ghadimi, Behrens, Hoffmann, Haensch, Birchmeier, Schlag: "Immunohistological analysis of E-cadherin, alpha-, beta- and gamma-catenin expression in colorectal cancer: implications for cell adhesion and signaling." in: European journal of cancer (Oxford, England : 1990), Vol. 35, Issue 1, pp. 60-5, 1999

Zschiesche, Schönborn, Behrens, Herrenknecht, Hartveit, Lilleng, Birchmeier: "Expression of E-cadherin and catenins in invasive mammary carcinomas." in: Anticancer research, Vol. 17, Issue 1B, pp. 561-7, 1997

Moll, Mitze, Frixen, Birchmeier: "Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas." in: The American journal of pathology, Vol. 143, Issue 6, pp. 1731-42, 1994

Böhm, Totzeck, Birchmeier, Wieland: "Differences of E-cadherin expression levels and patterns in primary and metastatic human lung cancer." in: Clinical & experimental metastasis, Vol. 12, Issue 1, pp. 55-62, 1994

Otto, Birchmeier, Schmidt, Hinke, Schipper, Rübben, Raz: "Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas." in: Cancer research, Vol. 54, Issue 12, pp. 3120-3, 1994

Mayer, Johnson, Leitl, Jauch, Heiss, Schildberg, Birchmeier, Funke: "E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration." in: Cancer research, Vol. 53, Issue 7, pp. 1690-5, 1993

Frixen, Behrens, Sachs, Eberle, Voss, Warda, Löchner, Birchmeier: "E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells." in: The Journal of cell biology, Vol. 113, Issue 1, pp. 173-85, 1991

Schipper, Frixen, Behrens, Unger, Jahnke, Birchmeier: "E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis." in: Cancer research, Vol. 51, Issue 23 Pt 1, pp. 6328-37, 1991